Every Form 4 that Aldeyra Therapeutics Inc (ALDX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALDX filings page.
Director Nancy Miller-Rich received two stock option awards from Aldeyra Therapeutics, Inc. These options allow her to buy 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share, with an expiration date of June 8, 2036.
Each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date. Vesting is conditioned on her continued service on the Board of Directors and, for the larger grant, on the Compensation Committee through the applicable vesting date. These are compensation-related grants, not open-market purchases or sales.
Aldeyra Therapeutics director Douglas Richard received new stock option awards. The Form 4 shows three option grants to buy Common Stock at an exercise price of $1.72 per share, covering 2,323, 19,909, and 70,000 underlying shares, respectively.
Each grant becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided he continues serving in the specified roles: as a member of the Board, as Chairperson of the Board, and as a member of the Nominating/Corporate Governance Committee.
Aldeyra Therapeutics director Gary M. Phillips received three stock option grants. On the reported date, he was awarded options to buy 70,000, 6,636 and 4,977 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable on the one-year anniversary of the grant date, if he continues serving on the Board and its Compensation and Audit Committees as applicable.
Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation. One option for 2,323 shares of common stock and another for 70,000 shares were granted with an exercise price of $1.72 per share and an expiration date of June 8, 2036.
Each grant becomes exercisable for 100% of the underlying shares on the one-year anniversary of the grant date. Vesting is conditioned on Clark providing continuous service, respectively, as a member of the Board of Directors and of the Nominating/Corporate Governance Committee through the applicable vesting date.
Aldeyra Therapeutics director Neal Walker received two new stock option grants. On the grant date, he was awarded options for 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable one year after grant, contingent on his continued Board and Compensation Committee service.
Aldeyra Therapeutics director Ben Bronstein received three stock option awards, each covering rights to buy common stock at an exercise price of $1.72 per share. The grants cover 4,977, 5,309, and 70,000 underlying shares, respectively, and are reported as compensation-related acquisitions rather than market purchases.
According to the filing, each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided Bronstein continues serving on the Board of Directors and, for two grants, on the Nominating/Corporate Governance and Audit Committees through the applicable vesting dates. All options are scheduled to expire on June 8, 2036 if not exercised.
Aldeyra Therapeutics, Inc. director Darlene M. Deptula‑Hicks received two stock option grants to acquire common stock at an exercise price of $1.72 per share.
One option for 9,756 shares vests in equal annual installments over three years after June 9, 2026. A second option for 84,557 shares becomes exercisable for all shares on the one‑year anniversary of the grant date if she continues serving on the Audit Committee. Both options expire on June 8, 2036.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady reported an open-market purchase of common stock. He bought 250,000 shares of Aldeyra common stock at a weighted average price of $1.6738 per share in transactions on June 3, 2026. Following this purchase, he directly owns 1,721,298 shares of Aldeyra common stock. The footnote explains that the shares were acquired in multiple trades at prices ranging from $1.64 to $1.70 per share.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady received new equity-based compensation awards. He was granted a stock option covering 1,880,510 shares of common stock at an exercise price of $1.77 per share. This option vests in equal monthly installments over 48 months of continuous service after January 1, 2026 and expires on March 26, 2036.
Brady was also awarded 632,318 bonus units, which vest in equal annual installments over four years beginning on March 27, 2026, contingent on continued service. Each vested bonus unit entitles him to a cash payment equal to the closing price per share of Aldeyra’s common stock on the payment date, made on the earlier of four years from grant or a Change of Control. These are compensation grants, not open-market share purchases or sales.
Aldeyra Therapeutics director Richard Douglas bought more company stock in the open market. He acquired 70,000 shares of common stock in an open-market purchase at $1.40 per share. Following this transaction, he directly owns 195,000 shares, indicating a larger personal stake in Aldeyra Therapeutics.
Aldeyra Therapeutics, Inc. Principal Financial Officer Michael Alfieri reported an open-market purchase of common stock. On this transaction date, he bought 5,000 shares at a price of $1.42 per share. Following the purchase, his direct ownership increased to 7,500 common shares.